Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Terminated Phase 2 Interventional Results available

An Open-Label, Safety and Tolerability Study of Chronic Intermittent Use of Diazepam Nasal Spray.

ClinicalTrials.gov ID: NCT02316847

Public ClinicalTrials.gov record NCT02316847. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 21, 2026, 1:44 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Multi-center, Open-label, Study of Safety and Tolerability of Chronic Intermittent Usage of Diazepam Nasal Spray in Adolescents and Adult Patients With Cluster Seizures, Including Assessment of Olfaction and Reported Changes in Taste.

Study identification

NCT ID
NCT02316847
Recruitment status
Terminated
Study type
Interventional
Phase
Phase 2
Lead sponsor
Acorda Therapeutics
Industry
Enrollment
126 participants

Conditions and interventions

Conditions

Interventions

  • diazepam nasal spray Drug

Drug

Eligibility (public fields only)

Age range
12 Years to 65 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Nov 30, 2014
Primary completion
Jun 30, 2016
Completion
Aug 31, 2016
Last update posted
Jul 29, 2018

2014 – 2016

United States locations

U.S. sites
33
U.S. states
21
U.S. cities
29
Facility City State ZIP Site status
Acorda Site #227 Phoenix Arizona 85054
Acorda Site #204 Little Rock Arkansas 72205
Acorda Site #213 Los Angeles California 90095
Acorda Site #220 Orange California 92868
Acorda Site #206 Orlando Florida 32819
Acorda Site #241 Port Charlotte Florida 33592
Acorda Site #231 Tallahassee Florida 32308
Acorda Site #201 Tampa Florida 33606
Acorda Site #234 Tampa Florida 33609
Acorda Site #217 Augusta Georgia 30912
Acorda Site #232 Honolulu Hawaii 96817
Acorda Site #225 Fort Wayne Indiana 46804
Acorda Site #226 Ames Iowa 50010
Acorda Site #202 Bethesda Maryland 20817
Acorda Site #212 Boston Massachusetts 02115
Acorda Site #214 Boston Massachusetts 02115
Acorda Site #208 Boston Massachusetts 02215
Acorda Site #216 Kansas City Missouri 64111
Acorda Site #205 St Louis Missouri 63131
Acorda Site #222 Hackensack New Jersey 07601
Acorda Site #223 New York New York 10016
Acorda Site #233 Rochester New York 14642
Acorda Site #230 Portland Oregon 97239
Acorda Site #219 Philadelphia Pennsylvania 19104
Acorda Site #237 Philadelphia Pennsylvania 19107
Acorda Site #203 Charleston South Carolina 29425
Acorda Site #235 Memphis Tennessee 38103
Acorda Site #218 Nashville Tennessee 37232
Acorda Site #221 Dallas Texas 75251
Acorda Site #229 Houston Texas 77030
Acorda Site #215 Richmond Virginia 23298
Acorda Site #224 Renton Washington 98057
Acorda Site #210 Madison Wisconsin 53792

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT02316847, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jul 29, 2018 · Synced Jul 21, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT02316847 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →